

# Topical Fenticonazole in Dermatology and Gynaecology

## Current Role in Therapy

Stefano Veraldi<sup>1</sup> and Rodolfo Milani<sup>2</sup>

- 1 Institute of Dermatological Sciences, University of Milan, I.R.C.C.S. Foundation, Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena, Milan, Italy
- 2 Università degli Studi Bicocca, Direttore di Clinica ostetrica e ginecologia, Azienda Ospedaliera San Gerardo di Monza, Milan, Italy

---

## Contents

|                                              |      |
|----------------------------------------------|------|
| Abstract.....                                | 2183 |
| 1. Results .....                             | 2185 |
| 1.1 Dermatological Indications .....         | 2185 |
| 1.1.1 Open-Label/Noncomparative Studies..... | 2185 |
| 1.1.2 Randomized Controlled Trials.....      | 2188 |
| 1.2 Gynaecological Indications .....         | 2189 |
| 1.2.1 Microbiological Efficacy .....         | 2189 |
| 1.2.2 Clinical Efficacy.....                 | 2192 |
| 1.3 Tolerability .....                       | 2192 |
| 2. Conclusions .....                         | 2193 |

---

## Abstract

Fenticonazole is an imidazole derivative with a broad spectrum of antimycotic activity against dermatophytes and yeasts in *in vitro* and clinical studies. Fenticonazole exerts its unique antimycotic mechanism of action in the following three ways: (i) inhibition of the secretion of protease acid by *Candida albicans*; (ii) damage to the cytoplasmic membrane; and (iii) by blocking cytochrome oxidases and peroxidises. Fenticonazole has also been shown to exhibit antibacterial action, with a spectrum of activity that includes bacteria commonly associated with superinfected fungal skin and vaginal infections, and antiparasitic action against the protozoan *Trichomonas vaginalis*. Therefore, fenticonazole may be an ideal topical alternative to multi-agent treatment of mixed infections involving mycotic, bacterial, dermatophyte and/or *Trichomonas* spp.

Open-label clinical studies show that fenticonazole, in different pharmaceutical preparations administered once or twice daily, is effective in the treatment of superficial mycoses of the skin. In particular, fenticonazole is very effective (often with 100% of patients achieving a negative mycological assay) in pityriasis versicolor and candidiasis. For example, a large (n = 760) study showed fenticonazole 2% cream, spray or powder to be associated with a mycological response in 100% of patients with pityriasis versicolor, 96.3% of those with tinea infections and 95.2% of patients with *Candida* infections. Comparative clinical

studies show fenticonazole once or twice daily to be at least as effective as six different topical antimycotics (miconazole, clotrimazole, econazole, bifonazole, naftifine and cyclopyroxolamine) in the treatment of superficial mycoses of the skin. Intravaginal administration of fenticonazole is associated with a high rate of microbiological efficacy in patients with vaginal candidiasis, trichomoniasis, mixed infection and bacterial vaginosis. Intravaginal fenticonazole is at least as effective as clotrimazole and shows similar efficacy to miconazole in patients with vaginal candidiasis. Fenticonazole has a rapid onset of action and clinical efficacy is generally observed within days of commencing treatment.

Topical fenticonazole is very well tolerated; adverse events are generally mild to moderate in severity and transient. The most frequent adverse events are burning sensation/cutaneous irritation and itch when applied to the skin. In a large, open-label study in superficial mycoses of the skin, the incidence of adverse events was <5% and these were rarely responsible for treatment discontinuation. Burning sensation is the most common adverse event seen with fenticonazole when administered intravaginally. However, this symptom of vaginal fungal infection was often present in patients prior to drug administration.

Given the rising incidence of superficial fungal, and possibly mixed, infections, topical fenticonazole represents an important part of the topical antimycotic armamentarium.

The incidence of fungal infections is rising as a result of increasing numbers of immunocompromised individuals, such as the elderly and patients receiving immunosuppressants for co-morbid conditions, and patients with hyperglycaemia/uncontrolled diabetes mellitus;<sup>[1]</sup> this may also be true for mixed mycotic/bacterial infections of the skin and vulvovaginal tissues. Mixed infections can be controlled with a combination of antifungal, antibacterial and corticosteroid therapy. This approach is effective, but can induce resistance and is associated with a high rate of systemic and local adverse events.

Imidazole derivatives control fungal infections by damaging the fungal cell membrane via inhibition of the fungal P450 isozyme, which is required to convert lanosterol to ergosterol, an essential component of fungal cell membrane synthesis.<sup>[2]</sup>

Fenticonazole is an effective and well tolerated broad spectrum imidazole antifungal agent that is used in the topical treatment of fungal infections of the skin and vulvovaginal tissues. It has long been known from *in vitro*<sup>[3]</sup> and clinical<sup>[4]</sup> studies that fenticonazole, as with other imidazole derivatives, has high *in vitro* activity against a wide range of

fungal pathogens, as well as Gram-positive bacteria. Morphological studies suggest that fenticonazole blocks yeast enzymatic activity (cytochrome oxidase and peroxidase)<sup>[5,6]</sup> and inhibits the synthesis, rather than the activity, of secretory aspartate acid proteinase, which is a virulence enzyme of *Candida albicans* that has been correlated with adherence of the yeast to epithelial cells.<sup>[7-9]</sup> This property has also been observed with fluorocytosine, but not with fluconazole, ketoconazole or miconazole.<sup>[7]</sup>

*In vitro* studies suggest that fenticonazole may have a role in the treatment of mixed mycotic and bacterial infections, such as fungal skin infections superinfected with *Staphylococcus aureus*, coryneforms and streptococci.<sup>[10]</sup> Fenticonazole has also demonstrated *in vitro* activity against bacteria that are commonly associated with vaginosis, such as *Bacteroides* isolates of the *Bacteroides melaninogenicus*-*B. oralis* group, *Gardnerella vaginalis*, *Mobiluncus* spp. and anaerobic, Gram-positive cocci.<sup>[10]</sup>

The objective of this review is to present the current clinical data on the use of fenticonazole, including the small amount of recent, interesting

data on its efficacy in mixed infections, and to discuss the ongoing clinical role of fenticonazole in dermatological and gynaecological indications. Relevant clinical studies for fenticonazole were identified and selected for inclusion in this review from systematic literature searches. Two separate literature searches were performed using the following criteria: 1980 to the present; all languages; human clinical study or review; on MEDLINE, EMBASE and AdisBase (a proprietary database of Wolters Kluwer Health | Adis), and deduplicated for (i) Fenticonazole AND Gynaecology; and (ii) Fenticonazole AND Dermatology.

## 1. Results

### 1.1 Dermatological Indications

Fenticonazole has been investigated for the treatment of dermatological infections in 24 clinical studies (table I). Fourteen studies were randomized, double-blind or comparator-controlled studies<sup>[11-24]</sup> and ten were open-label, noncomparative trials.<sup>[25-34]</sup> Fenticonazole was compared with miconazole,<sup>[15,16,23,24]</sup> econazole,<sup>[19,21,22]</sup> bifonazole,<sup>[14,18]</sup> naftifine,<sup>[12,20]</sup> clotrimazole,<sup>[17]</sup> cyclopyroxolamine<sup>[13]</sup> and placebo.<sup>[11]</sup> Fenticonazole 2% cream was administered in the majority of studies.<sup>[11,12,15-19,23-28,30-32]</sup> Other formulations included 2% solution, lotion or spray,<sup>[13,14,20,21,25,26,30-33]</sup> 2% foam,<sup>[22]</sup> 2% gel<sup>[34]</sup> or 2% powder.<sup>[11,30]</sup> Inclusion criteria in studies were tinea pedis,<sup>[11]</sup> cutaneous mycoses,<sup>[12,13,20,21]</sup> pityriasis versicolor,<sup>[14-16,22,25,26]</sup> dermatophytosis,<sup>[15,16,34]</sup> candidiasis,<sup>[16]</sup> dermatomycoses,<sup>[17-19,23-25,32]</sup> superficial mycoses,<sup>[27-32]</sup> or otomycoses.<sup>[33]</sup> Six studies are available as English abstracts only.<sup>[22,26,27,29,31,33]</sup>

#### 1.1.1 Open-Label/Noncomparative Studies

The first study on the efficacy and tolerability of fenticonazole was published in 1984 by Lepine et al.<sup>[34]</sup> Twenty-eight patients with dermatophytosis were treated with fenticonazole 2% gel twice daily for 28 days. Clinical resolution was seen in all of the 25 patients who completed the study. A year later, Persi and Rebora<sup>[28]</sup> treated 46 patients with superfi-

cial mycoses with fenticonazole 2% cream for 13–28 days. Clinical and mycological remission was obtained in 35 patients (76.1%). In 1986, Clerico<sup>[31]</sup> used fenticonazole 2% lotion, spray or cream in 45 patients and observed good or excellent clinical results in all patients. Different formulations (fenticonazole 2% cream and fenticonazole 2% lotion, respectively) were used to treat 30 patients with dermatomycoses and 10 patients with pityriasis versicolor.<sup>[25]</sup> Fenticonazole was applied twice daily for 5 weeks. Twenty-six of 30 patients with dermatomycoses and all 10 patients with pityriasis versicolor were cured (36 of 40 patients [90%]).

In 1987, fenticonazole, used once daily for the first time, in 30 patients with candidiasis and pityriasis versicolor<sup>[27]</sup> demonstrated clinical and mycological healing in 100% of patients after 28 days of treatment, and in eight of ten patients with epidermomycosis after 32 days. The once-daily application of fenticonazole is based on the fact that the drug is retained on the skin for 72 hours after a single application in pretreated guinea pigs.<sup>[35]</sup> This property of fenticonazole was subsequently exploited in the treatment of recurrent dermatomycoses such as tinea pedis.<sup>[11]</sup> The most important open-label, multicentre clinical trial was published in 1988.<sup>[30]</sup> Fenticonazole cream, spray or powder was applied once or twice daily in 760 patients with superficial mycoses. A negative mycological assay was obtained within 28–35 days of treatment. The clinical and mycological response rate was very high in pityriasis versicolor (100%) and in candidiasis (95%). This study suggested that once-daily application of fenticonazole may induce a high patient compliance.

Clinical and mycological remission was obtained in 51 of 51 patients with superficial mycoses<sup>[29]</sup> and in 30 of 30 patients with pityriasis versicolor<sup>[26]</sup> in studies in which fenticonazole cream or lotion was applied twice daily for 2 weeks. In 27 of 27 patients treated twice daily with fenticonazole cream or spray, a clinical and mycological cure was achieved after 4 weeks.<sup>[32]</sup> In this study, determination of fenticonazole plasma concentrations confirmed that the drug is poorly absorbed.

**Table 1.** Summary of clinical trials of fenticonazole (FEN) in the treatment of dermatological infections

| Study (year)                               | Design (timepoint of efficacy evaluation) | Diagnosis             | Treatment (no. of pts)                                       | Primary outcomes                                                                                                                  |                                                                                                      |
|--------------------------------------------|-------------------------------------------|-----------------------|--------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
|                                            |                                           |                       |                                                              | microbiological efficacy                                                                                                          | tolerability                                                                                         |
| Albanese et al. <sup>[11]</sup> (1992)     | R, DB (4 mo)                              | Tinea pedis           | FEN 2% CR + 2% PDR <sup>a</sup> (15)<br>PL <sup>a</sup> (15) | Relapse seen in 17% of FEN and 50% of PL recipients                                                                               | Tolerability scores were excellent or good in all cases with FEN and PL                              |
| Altmeyster et al. <sup>[13]</sup> (1990)   | R, DB (2–3 wk post treatment)             | Cutaneous mycoses     | FEN 2% SOL 2–4 wk (50)<br>CYC 1% SOL 2–4 wk (50)             | Positive microscopic findings were seen in 6.5% of FEN and 10.6% of CYC recipients following drug-free period                     | Treatment was terminated early in 1 FEN pt due to slight itching                                     |
| Altmeyster et al. <sup>[12]</sup> (1990)   | R, DB, MC (2–3 wk post treatment)         | Cutaneous mycoses     | FEN 2% CR 2–4 wk (49)<br>NAF 2% CR 2–4 wk (48)               | Positive microscopic findings were seen in 15.38% of FEN and 11.36% of NAF recipients following drug-free period                  | No adverse events were reported                                                                      |
| Fioroni et al. <sup>[32]</sup> (1990)      | OL (4 wk)                                 | Dermatomycoses        | FEN 2% CR + SPR ≤4 wk (27)                                   | Mycological results were negative in 100% of pts after 4 wk                                                                       | No adverse events were reported                                                                      |
| Fusetti et al. <sup>[33b]</sup> (1990)     | OL (NR)                                   | Otomycoses            | FEN 2% SOL (50)                                              | Complete mycological remission was achieved in 100% of pts                                                                        | NR                                                                                                   |
| Odeh et al. <sup>[21]</sup> (1990)         | R, DB, MC (2–3 wk post treatment)         | Cutaneous mycoses     | FEN 2% LOT 2–4 wk (92)<br>ECO 1% LOT 2–4 wk (93)             | At endpoint, 8% of FEN and 13.4% of ECO recipients were positive for fungi by microscopy and 0% and 5.06% positive by culture     | 1 FEN recipient reported severe redness and itching and 1 reported mild local burning on application |
| Di Silverio et al. <sup>[26b]</sup> (1989) | OL (NR)                                   | Pityriasis versicolor | FEN 2% CR or LOT (30)                                        | Disappearance of yeast was obtained on average after 2 wk                                                                         | NR                                                                                                   |
| Leiste et al. <sup>[20]</sup> (1989)       | R, DB, MC (2–3 wk post treatment)         | Cutaneous mycoses     | FEN 2% SOL 2–4 wk (50)<br>NAF 1% SOL 2–4 wk (50)             | At endpoint, 8.3% of FEN and 11.1% of NAF recipients were positive for fungi by microscopy and 5.7% and 14.7% positive by culture | 3 FEN and 4 NAF recipients reported burning sensation on application                                 |
| Rabbiosi et al. <sup>[22b]</sup> (1989)    | R, DB (NR)                                | Pityriasis versicolor | FEN 2% foam (20)<br>ECO 1% foam (20)                         | Mycological healing was seen in 100% of pts in both groups                                                                        | 1 pt receiving FEN discontinued treatment due to cutaneous irritation                                |
| Aste et al. <sup>[14]</sup> (1988)         | R, DB (21 d)                              | Pityriasis versicolor | FEN 2% LOT 3 wk (23)<br>BIF 1% LOT 3 wk (23)                 | 22% of FEN and 30% of BIF recipients were cured at 21 d                                                                           | 2 pts receiving FEN reported transient desquamation                                                  |
| Jung et al. <sup>[18]</sup> (1988)         | R, DB (28 d)                              | Dermatomycoses        | FEN 2% CR ≤4 wk (21)<br>BIF 1% CR ≤4 wk (20)                 | 95% of FEN and 85% of BIF recipients were negative for fungi at endpoint                                                          | No adverse events were reported                                                                      |
| Pizzino et al. <sup>[29b]</sup> (1988)     | OL (NR)                                   | Superficial mycoses   | FEN (51) <sup>c</sup>                                        | FEN showed "marked clinical efficacy"                                                                                             | Local and systemic tolerance was good                                                                |
| Sartani et al. <sup>[30]</sup> (1988)      | OL, MC (28–35 d)                          | Superficial mycoses   | FEN 2% CR, SPR or PDR (760)                                  | Mycological response was seen in 100% of pts with pityriasis versicolor, 96.3% with tinea and 95.2% with <i>Candida</i>           | Adverse events were reported in 3.8% of pts; drug discontinuation occurred in ~1.0%                  |

Continued next page

Table 1. Contd

| Study (year)                               | Design (timepoint of efficacy evaluation) | Diagnosis                                              | Treatment (no. of pts)                                                                 | Primary outcomes microbiological efficacy                                                                       | tolerability                                                                         |
|--------------------------------------------|-------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Vannini et al. <sup>[24]</sup> (1988)      | R, DB (35 d)                              | Dermatomycoses                                         | FEN 2% CR od 3 wk (20)<br>FEN 2% CR bid 3 wk (20)<br>MIC 2% CR bid 3 wk (20)           | 80% FEN od, 90% FEN bid and 90% MIC recipients were negative for fungi on microscopic examination at endpoint   | 1 FEN od, 2 FEN bid and 1 MIC recipient reported mild itching and increased erythema |
| Aste et al. <sup>[25]</sup> (1987)         | OL (5 wk)                                 | Dermatomycoses or pityriasis versicolor                | FEN 2% CR or LOT 5 wk (40 pts with dermatomycoses + 10 pts with pityriasis versicolor) | Mycological cure was seen in 100% of pts with pityriasis versicolor and 86.6% with dermatomycoses               | Mild, self-limiting desquamation was reported in 7 pts                               |
| Clerico and Ribuffo <sup>[16]</sup> (1987) | R (30 d)                                  | Pityriasis versicolor, candidiasis, or dermatophytosis | FEN 2% CR 30 d (20)<br>MIC 2% CR 30 d (20)                                             | Microscopic and cultural analysis remained positive in 5% of FEN and 10% of MIC recipients                      | No adverse events were reported                                                      |
| Fioroni et al. <sup>[27]b</sup> (1987)     | OL (NR)                                   | Superficial mycoses                                    | FEN 2% CR (30)                                                                         | 100% of pts with candidiasis or pityriasis versicolor and 80% with tinea pedis "healed"                         | Irritative contact dermatitis reported in 2 pts                                      |
| Athow-Frost et al. <sup>[15]</sup> (1986)  | R, DB, MC (2–3 wk post treatment)         | Dermatophytosis or pityriasis versicolor               | FEN 2% CR ≤4 wk (28)<br>MIC 2% CR ≤4 wk (25)                                           | 92% of FEN and 79% of MIC recipients had negative mycology at endpoint                                          | 1 pt receiving MIC reported dry skin on the foot; no other adverse events            |
| Clerico <sup>[31]b</sup> (1986)            | OL (NR)                                   | Superficial mycoses                                    | FEN 2% LOT, SPR or CR (45)                                                             | "Efficacy was good"                                                                                             | "Tolerability was good"                                                              |
| Finzi et al. <sup>[17]</sup> (1986)        | R, DB (4 wk)                              | Dermatomycoses                                         | FEN 2% CR ≤4 wk (21)<br>CLO 1% CR ≤4 wk (21)                                           | "Definite cure" was obtained in 86% of FEN and 62% of CLO recipients                                            | No adverse events were reported                                                      |
| Kokoschka et al. <sup>[19]</sup> (1986)    | R, DB (4 wk)                              | Dermatomycoses                                         | FEN 2% CR ≤4 wk (28)<br>ECO 1% CR ≤4 wk (24)                                           | Clinical and mycological healing was seen in 15/28 (54%) of FEN recipients and in 10/24 (42%) of ECO recipients | No adverse events were reported                                                      |
| Perisi and Rebora <sup>[26]</sup> (1985)   | OL (28 d)                                 | Superficial mycoses                                    | FEN 2% CR ≤4 wk (46)                                                                   | "Clinical cure" was experienced by 76.1% of pts                                                                 | No adverse events were reported                                                      |
| Lepine et al. <sup>[34]</sup> (1984)       | OL (28 d)                                 | Dermatophytosis                                        | FEN 2% gel 28 d (28)                                                                   | Clinical resolution was seen in 100% of pts ending the study                                                    | Treatment was interrupted in 3 pts due to erythema or oedema at site of application  |
| Stetter <sup>[23]</sup> (1984)             | R, DB (4–8 wk post treatment)             | Dermatomycoses                                         | FEN 2% CR ≤4 wk (NR <sup>d</sup> )<br>MIC 2% CR ≤4 wk (NR <sup>d</sup> )               | NR                                                                                                              | No adverse events were reported                                                      |

a Pts were treated with FEN 2% CR and 2% PDR for a month or until cured and subsequently randomized to FEN or PL.

b Available as English abstract only.

c Formulation NR in abstract.

d Total population for FEN plus MIC groups = 30 pts.

**bid** = twice daily; **BIF** = bifonazole; **CLO** = clotrimazole; **CR** = cream; **CYC** = cyclopyroxolamine; **DB** = double-blind; **ECO** = econazole; **LOT** = lotion; **MC** = multicentre; **MIC** = miconazole; **NAF** = natifine; **NR** = not reported; **od** = once daily; **OL** = open-label; **PDR** = powder; **PL** = placebo; **pts** = patient; **R** = randomized; **SOL** = solution; **SPR** = spray.

Finally, complete clinical and mycological remission was observed in all patients ( $n = 50$ ) affected by otomycoses and treated with fenticonazole for 2 weeks.<sup>[33]</sup>

### 1.1.2 Randomized Controlled Trials

#### Comparison with Miconazole

The first double-blind study of fenticonazole versus miconazole was published in 1984 by Stetter.<sup>[23]</sup> Thirty patients with symmetrical lesions caused by dermatophytes were treated. Both antimycotics were used as a 2% cream, twice daily, until healing occurred (maximum duration of the treatment was 28 days). More rapid healing of the lesions and faster disappearance of symptoms was recorded in patients receiving fenticonazole. Fenticonazole was compared with miconazole in a randomized, double-blind, multicentre study in 53 patients with dermatophytosis and pityriasis versicolor.<sup>[15]</sup> Both drugs were applied twice daily for 4 weeks. No statistically significant differences between the two drugs were recorded. However, negative mycological examination was obtained in 23 of 25 patients (92%) treated with fenticonazole and in 19 of 24 patients (79%) treated with miconazole.

Superimposable results were obtained in 40 patients with pityriasis versicolor, candidiasis or dermatophytosis who were treated with fenticonazole or miconazole cream. Clinical healing was observed in 16 patients (plus improvement in four patients) in the group treated with fenticonazole compared with 14 patients (plus improvement in five patients) in the group treated with miconazole.<sup>[16]</sup> In the most recent double-blind trial using miconazole as the comparator, fenticonazole (once or twice daily) was compared with miconazole applied twice daily in 60 patients with dermatomycoses. No differences were observed between the three groups of patients. However, the authors underlined the improvement in patient compliance with once daily application.<sup>[24]</sup>

#### Comparison with Clotrimazole

Only one double-blind study comparing fenticonazole 2% cream versus clotrimazole 1% cream has been published; both agents were administered twice daily for 4 weeks.<sup>[17]</sup> Eighteen lesions of 21

treated with fenticonazole and 13 lesions of 21 treated with clotrimazole were cured.

#### Comparison with Econazole

Three randomized, double-blind trials of fenticonazole 2% versus econazole 1% have been published.<sup>[19,21,22]</sup> In the first study, 52 patients with dermatomycoses were treated twice daily for 4 weeks.<sup>[19]</sup> Clinical and mycological healing was achieved in 15 of 28 patients treated with fenticonazole and in only 10 of 24 patients treated with econazole. Furthermore, the onset of action of fenticonazole was more rapid than that of econazole, an observation previously published by Stetter.<sup>[23]</sup> In the study by Rabbiosi et al.,<sup>[22]</sup> fenticonazole 2% foam was compared with econazole 1% foam in 40 patients with pityriasis versicolor. Both products were applied once daily for 2 weeks. Negative mycological examination was obtained in 100% of patients in both treatments. The third trial on fenticonazole versus econazole is based on the largest group of patients with cutaneous mycoses.<sup>[21]</sup> Both drugs were applied as lotions once daily for 2–4 weeks. At the end of the study, 72.7% of patients treated with fenticonazole were considered clinically and mycologically recovered compared with 71% of patients treated with econazole.

#### Comparison with Bifonazole

Fenticonazole was compared with bifonazole in two randomized, double-blind studies.<sup>[14,18]</sup> In 41 patients with dermatomycosis, fenticonazole 2% cream or bifonazole 1% cream was applied once daily for 4 weeks.<sup>[18]</sup> The authors observed, once again, a faster therapeutic activity of fenticonazole compared with bifonazole. In the second trial,<sup>[14]</sup> 46 patients with pityriasis versicolor were treated with fenticonazole 2% lotion or bifonazole 1% lotion, both applied once daily for 3 weeks. The authors stated that the efficacy of fenticonazole is comparable with that of bifonazole.

#### Comparison with Ketoconazole

A comparative study of *in vitro* activity and clinical efficacy in 51 patients with superficial skin mycoses showed that fenticonazole had similar or superior activity against the isolated pathogens



and was at least as effective as ketoconazole, miconazole and intraconazole.<sup>[29]</sup> In a clinical comparison of fenticonazole with ketoconazole and nystatin in 80 patients with erythematous chronic candidiasis, a significant reduction in oral lesions was seen in all groups ( $p < 0.0001$ ) with no significant between group difference in efficacy.<sup>[36]</sup>

#### Comparison with Naftifine

Two studies compared the efficacy of fenticonazole with naftifine in patients with cutaneous mycoses. In a double-blind, multicentre trial, 100 patients were treated with fenticonazole 2% spray or naftifine 1% spray once daily for 2–4 weeks.<sup>[20]</sup> At the end of the study, about 90% of patients in both groups were cured or greatly improved, both mycologically and clinically. In another double-blind, multicentre study in 97 patients,<sup>[12]</sup> fenticonazole 2% cream was compared with naftifine 2% cream (once daily application for 2–4 weeks). Overall, 43 of 46 patients in the fenticonazole group and 43 of 48 in the naftifine group were judged to be clinically and mycologically healed.

#### Comparison with Cyclopyroxolamine

Altmeyer et al.<sup>[13]</sup> also studied the efficacy of fenticonazole spray versus cyclopyroxolamine 1% spray in a double-blind trial. Both antimycotics were applied once daily for 2–4 weeks in 100 patients. Clinical improvement was seen in 91.8% of patients in the fenticonazole group versus 89.8% of patients in the cyclopyroxolamine group.

### 1.2 Gynaecological Indications

Fenticonazole has been investigated in the treatment of vulvovaginitis caused by *Candida* spp., *Trichomonas* spp., mixed infections or bacterial infections in 17 studies (table II). Four studies were double-blind, placebo- or comparator-controlled,<sup>[4,37–39]</sup> two were single (investigator) blind,<sup>[40,41]</sup> and the remainder were open-label.<sup>[42–52]</sup> Fenticonazole was compared with placebo,<sup>[4,38,39]</sup> clotrimazole<sup>[37,40,41,45]</sup> or miconazole<sup>[46]</sup> in studies. Fenticonazole intravaginal capsules or ovules were used in all of the studies except five, which used 2%

cream,<sup>[4,37]</sup> or fenticonazole ovules with or without cream<sup>[50,52]</sup> or vaginal wash,<sup>[51]</sup> fenticonazole vaginal capsules were compared with fenticonazole cream in one study.<sup>[47]</sup> Inclusion criteria in studies were vaginal candidiasis,<sup>[37,40–42,45,47–52]</sup> vaginal trichomoniasis,<sup>[38,39,51]</sup> mixed infections<sup>[43,44]</sup> and bacterial vaginosis.<sup>[4]</sup> Five studies are available as English abstracts only.<sup>[4,42,46,51,52]</sup>

#### 1.2.1 Microbiological Efficacy

##### Vaginal Candidiasis

Fenticonazole intravaginal capsules, at doses of 600 mg or 1000 mg as a single dose or 200 mg daily for 3 days, 2% cream applied daily for 3 or 7 days, or a combination of fenticonazole intravaginal capsules plus cream or vaginal wash were effective at eradicating *Candida* spp. in 75–100% of patients and all organisms in 70–100% of patients with vaginal candidiasis.<sup>[37,40–42,45–52]</sup> ‘Mycologic cure’ was obtained in 92% of patients in a further study where the dosage of fenticonazole intravaginal capsules was not stated.<sup>[42]</sup> These eradication rates were obtained within 7 days in the majority of studies<sup>[40–42,45,46,48,49,52]</sup> and sustained for between 4 to 6 weeks in two trials.<sup>[37,51]</sup> Fenticonazole 600 mg or 1000 mg as a single dose or 200 mg daily for 3 days<sup>[49]</sup> and fenticonazole intravaginal capsules 200 mg or fenticonazole 2% cream used daily for 3 days<sup>[47]</sup> showed similar efficacy in open-label studies.

No significant differences in the proportion of patients negative for all organisms,<sup>[45]</sup> *Candida* spp.<sup>[40]</sup> or *C. albicans*<sup>[41]</sup> were seen after treatment with single doses of fenticonazole 600 mg or clotrimazole 500 mg. Moreover, *Candida* spp. were eliminated from a similar proportion of patients receiving fenticonazole cream or clotrimazole cream in a double-blind study.<sup>[37]</sup> Similar microbiological efficacy was seen at 7–10 days when fenticonazole 200 mg and miconazole 400 mg daily for 3 days were compared (both 97.5%).<sup>[46]</sup>

##### Vaginal Trichomoniasis

In three studies in patients with vaginal trichomoniasis, fenticonazole vaginal capsules 600 mg or 1000 mg administered as a single dose, with<sup>[51]</sup> or

**Table II.** Summary of clinical trials of fenticonazole (FEN) in the treatment of gynaecological infections. FEN was administered as an intravaginal capsule or ovule unless stated otherwise

| Study (year)                                 | Design (timepoint of efficacy evaluation) | Diagnosis                            | Treatment (no. of pts)                                                                         | Primary outcomes microbiological efficacy                                                                                                                      | tolerability                                                                                                        |
|----------------------------------------------|-------------------------------------------|--------------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Fernandez-Alba et al. <sup>[44]</sup> (2004) | OL, MC (8 d)                              | Mixed infections                     | FEN 1000 mg, d 1 + 3 (101)                                                                     | 90% of pts were negative for <i>Candida albicans</i> , 70% for <i>Trichomonas vaginalis</i> , 67% for <i>Gardnerella vaginalis</i> and 45% for mixed infection | No treatment-related adverse events reported                                                                        |
| Naud et al. <sup>[41a]</sup> (2003)          | R, DB (9 or 28 d)                         | Bacterial vaginosis                  | FEN 2% cream 5 g, d 1–7 (NR <sup>b</sup> )<br>PL (NR <sup>b</sup> )                            | The "cure rate" was significantly higher with FEN vs PL (85% vs 35%; $p = 0.003$ )                                                                             | Mild treatment-related adverse event was seen in 1 FEN recipient                                                    |
| Munoz Reyes et al. <sup>[46]</sup> (2002)    | R, OL (7–10 d)                            | Vaginal candidiasis                  | FEN 200 mg, d 1–3 (40)<br>MIC 400 mg, d 1–3 (40)                                               | Microbiological efficacy was considered satisfactory in 97.5% of pts in both groups                                                                            | Minor adverse events were seen in 0 FEN and 2 MIC recipients                                                        |
| Belaisch <sup>[42a]</sup> (1996)             | OL (7 d)                                  | Vaginal candidiasis                  | FEN d 1 (116)<br>FEN d 1 + 4 (58) [dose NR]                                                    | Mycological cure demonstrated by microscopic examination seen in 92% of pts                                                                                    | Treatment acceptance and tolerance rated as "good" or "excellent" by 92–98% of women                                |
| Scalabrino et al. <sup>[51a]</sup> (1996)    | OL, MC (28–35 d post treatment)           | Vaginal trichomoniasis ± candidiasis | FEN 1000 mg d 1 + vaginal wash × 5 (67)                                                        | Vaginal smears were negative for <i>T. vaginalis</i> and <i>Candida</i> spp. in 100% of pts                                                                    | Tolerability was judged as "excellent"                                                                              |
| Gorlero et al. <sup>[39]</sup> (1994)        | R, DB, MC (7 d)                           | Vaginal trichomoniasis               | FEN 600 mg, d 1 + 2 (21)<br>FEN 1000 mg, d 1 + 2 (20)<br>PL (20)                               | Significantly more pts receiving FEN 1000 mg (58.8%) or 600 mg (65.0%) were negative for <i>T. vaginalis</i> vs PL (15.0%) [ $p \leq 0.005$ ]                  | Mild or moderate burning sensation (2 pts) or burning sensation and discharge (1 pt) were reported with FEN 1000 mg |
| Gorlero et al. <sup>[38]</sup> (1992)        | R, DB (4 d)                               | Vaginal trichomoniasis               | FEN 600 mg, d 1 (32) <sup>c</sup><br>FEN 1000 mg d 1 (33) <sup>c</sup><br>PL (31) <sup>c</sup> | Significantly more pts receiving FEN 1000 mg (64%) were negative for all organisms vs FEN 600 mg (28%) and PL (16%) [ $p < 0.01$ ]                             | Tolerance to all treatments was generally good                                                                      |
| Bukovsky et al. <sup>[43]</sup> (1991)       | OL (7 d)                                  | Mixed infections                     | FEN 600 mg, d 1 [+ d 7 if symptoms persisted] (87)                                             | 45% of pts were negative for all organisms, 67% for <i>T. vaginalis</i> and 96% for <i>C. albicans</i>                                                         | No systemic or local adverse events reported                                                                        |
| Lawrence et al. <sup>[45]</sup> (1990)       | R, OL (7 d)                               | Vaginal candidiasis                  | FEN 600 mg, d 1 (75)<br>CLO 500 mg, d 1 (78)                                                   | A similar proportion of FEN and CLO recipients were negative for all organisms (92.0% vs 88.5%)                                                                | Mild, local and short-lasting burning (2 pts), soreness (2 pts) or vaginal discharge (1 pt) were reported with FEN  |

Continued next page



Table II. Contd

| Study (year)                             | Design (timepoint of efficacy evaluation) | Diagnosis           | Treatment (no. of pts)                                                            | Primary outcomes microbiological efficacy                                                                                   | tolerability                                                                                      |
|------------------------------------------|-------------------------------------------|---------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Schneider et al. <sup>[48]</sup> (1990)  | OL (7 d)                                  | Vaginal candidiasis | FEN 600 mg, d 1 [+ d 8 if symptoms persisted] (72)                                | 76% of pts were negative for all organisms and 92% negative for <i>C. albicans</i>                                          | No local or systemic adverse events were reported                                                 |
| Studd et al. <sup>[40]</sup> (1989)      | R, SB, MC (7 or 8 d)                      | Vaginal candidiasis | FEN 600 mg, d 1 (23)<br>CLO 500 mg, d 1 (20)                                      | A similar proportion of pts receiving FEN or CLO were negative for <i>Candida</i> spp. (78% vs 70%)                         | Short-lasting burning sensation was reported by 1 pt receiving FEN                                |
| Wiest et al. <sup>[41]</sup> (1989)      | R, SB (7 d)                               | Vaginal candidiasis | FEN 600 mg, d 1 (40)<br>CLO 500 mg, d 1 (40)                                      | A similar proportion of pts receiving FEN or CLO were negative for <i>C. albicans</i> (87.5% vs 92.5%)                      | No local or systemic adverse events were reported                                                 |
| De Cecco et al. <sup>[50]a</sup> (1988)  | OL, MC (NR)                               | Vaginal candidiasis | FEN cream, d 1–3 (31)<br>FEN 200 mg d 1–3 (192)<br>FEN 200 mg + cream, d 1–3 (46) | 80.6% of pts treated with cream, 83.1% treated with ovules and 83.8% treated with cream + ovules showed negative microscopy | Local adverse events were reported in 4 pts and systemic adverse events in 2 pts                  |
| Sartani et al. <sup>[47]</sup> (1988)    | OL, MC (≤15 d)                            | Vaginal candidiasis | FEN 200 mg, d 1–3 (334)<br>FEN 2% cream, d 1–3 (50)                               | A similar proportion of suppository and cream recipients were negative for all organisms (82.6% vs 70.0%)                   | Adverse events were reported in 9 vaginal capsule and 3 cream recipients                          |
| Scienza et al. <sup>[52]a</sup> (1987)   | OL (10 d)                                 | Vaginal candidiasis | FEN 200 mg od or FEN cream 100 mg bid, d 1–3 (20)                                 | Cultures were negative in 100% of pts 7 d after end of treatment                                                            | No local or systemic adverse events were reported                                                 |
| Wiest and Ruffman <sup>[49]</sup> (1987) | R, OL (7 d)                               | Vaginal candidiasis | FEN 200 mg, d 1–3 (20)<br>FEN 600 mg, d 1 (20)<br>FEN 1000 mg, d 1 (20)           | A similar proportion of pts receiving FEN 200, 600 or 1000 mg were negative for <i>C. albicans</i> (80%, 75% and 85%)       | Local burning sensation was reported by 1 pt receiving FEN 200 mg and 2 pts receiving FEN 1000 mg |
| Brewster et al. <sup>[37]</sup> (1986)   | R, DB (4–6 wk)                            | Vaginal candidiasis | FEN 2% cream 5 g, d 1–7 (27)<br>CLO 1% cream 5 g, d 1–7 (27)                      | Mycological swabs were negative in 96.0% of FEN pts and 96.1% of CLO pts                                                    | No local or systemic signs or symptoms of toxicity were reported                                  |

a Available as English abstract only.

b Total population for FEN plus PL groups = 47 pts.

c All women received an additional dose of fenticonazole 600 mg if still positive for *Trichomonas* at d 4 regardless of treatment allocation.

**bid** = twice daily; **CLO** = clotrimazole; **DB** = double-blind; **MC** = multicentre; **MIC** = miconazole; **NR** = not reported; **od** = once daily; **OL** = open-label; **PL** = placebo; **pts** = patients; **R** = randomized; **SB** = single-blind.

without<sup>[38]</sup> vaginal wash for 5 days, or daily for 2 days without vaginal wash<sup>[39]</sup> eradicated all organisms in 28–65% of patients at 7 days; eradication of *T. vaginalis* and *Candida* spp. was seen in 100% of patients at day 7. A single dose of fenticonazole 1000 mg was significantly more effective than fenticonazole 600 mg ( $p < 0.01$ ),<sup>[38]</sup> but no significant between-group difference was seen with fenticonazole 1000 mg or 600 mg administered daily for 2 days.<sup>[39]</sup>

#### Mixed Infections

Fenticonazole 600 mg as a single dose or 1000 mg on days 1 and 3 eradicated all organisms in 45% of patients after 7–8 days in two open-label studies.<sup>[43,44]</sup> At trial endpoint, 96% and 90% of patients were negative for *C. albicans*, and 67% and 70% were negative for *T. vaginalis* following treatment with fenticonazole 600 mg or 1000 mg, respectively.

#### Bacterial Vaginosis

A significantly higher microbiological cure rate was seen in patients with bacterial vaginosis treated with fenticonazole 2% cream 5 g daily for 7 days compared with placebo in a randomized, double-blind study (85% vs 35%;  $p = 0.003$ ) [timepoint not stated in abstract].<sup>[4]</sup> The recurrence rate was 11.8% in the fenticonazole group and 50% with placebo.

#### 1.2.2 Clinical Efficacy

In the majority of studies in patients with vaginal candidiasis, fenticonazole produced an improvement in signs and symptoms (e.g. erythema, pruritis/irritation/burning, discharge, oedema) within days and complete resolution of some or all symptoms in 52–100% of patients within 1 week.<sup>[40,42,45–48]</sup> In a randomized comparative study, symptom relief was considered satisfactory in 100% of patients receiving fenticonazole and 97.5% of patients receiving miconazole.<sup>[46]</sup>

In vaginal trichomoniasis, significantly greater symptomatic improvement (discharge, pruritus, erythema, oedema and overall score) was seen with single-dose fenticonazole 1000 mg compared with fenticonazole 600 mg or placebo at day 4 and 8 (all  $p < 0.05$ ), but no significant difference was seen

between fenticonazole 600 mg and placebo.<sup>[38]</sup> However, in a later, larger study, fenticonazole 1000 mg and 600 mg daily for 2 days, but not placebo, significantly improved all individual and total symptom scores from baseline at day 7, although no significant difference between the active groups was seen.<sup>[39]</sup>

Fenticonazole produced significant improvements from baseline in signs and symptoms of vaginal infection in two studies of mixed infections at 7–8 days (all  $p < 0.05$ ).<sup>[43,44]</sup>

#### 1.3 Tolerability

Fenticonazole 2% cream, lotion/solution, foam and powder were well tolerated when administered for up to 4 weeks in patients with cutaneous mycoses, pityriasis versicolor, dermatomycoses or tinea pedis. The most common adverse events associated with topical application of fenticonazole were burning sensation/cutaneous irritation and itch on application, which occurred in 1.1–6.0%<sup>[20–22]</sup> and 1.1–10.0%<sup>[13,21,24]</sup> of patients, respectively. However, in a large number of studies, no adverse events were reported.<sup>[12,16–19,23,28,32]</sup> In a large ( $n = 760$ ), open-label study, adverse events were reported in 3.8% of fenticonazole recipients and these precipitated drug discontinuation in approximately 1% of patients.<sup>[30]</sup> Other adverse events occurring in >1% of patients following topical application of fenticonazole included erythema<sup>[21,24]</sup> and desquamation.<sup>[14,25]</sup>

Fenticonazole vaginal capsules or ovules and cream were well tolerated in women with vaginal candidiasis, trichomoniasis, bacterial or mixed infections in studies of up to 4–6 weeks' duration. The most common treatment-related adverse event was burning sensation, often short-lasting and mild to moderate in severity, occurring in up to 7.3% of patients receiving fenticonazole;<sup>[37,39–41,43–49]</sup> however, this adverse event was reported in <1% of patients in six of these studies.<sup>[37,41,43,44,46,48]</sup> It is worth noting that burning sensation, a recognized symptom of vaginosis, was used as a parameter to symptom score eligible patients in several studies and was sometimes present at baseline. Other ad-

verse events reported in >1% of patients receiving fenticonazole vaginal capsules or cream were vaginal soreness (2.7%) and vaginal discharge (1.3%).<sup>[45]</sup>

## 2. Conclusions

Fenticonazole has broad spectrum activity against *Candida* spp. and other yeasts, dermatophytes, *Trichomonas* spp. and many of the bacteria commonly associated with skin and vaginal infections. Fenticonazole is the only imidazole antifungal agent to demonstrate single-dose and dose-dependent suppression of candidal proteinase secretion *in vitro*. Fenticonazole provides rapid control and is well tolerated in a variety of skin and vaginal infections. No systemic effects and no major local tolerability issues have been reported in over 20 years of clinical use. Recent *in vitro* studies have suggested that fenticonazole may be effective in the treatment of mixed infections involving mycotic, bacterial, dermatophyte and/or *Trichomonas* organisms, and this has been shown in several clinical studies. Although fenticonazole is one of the earlier imidazoles developed, recent studies have continued to demonstrate its clinical usefulness as a low-cost, first-line agent in the treatment of skin and vulvovaginal infections. In view of the increasing incidence of mixed aetiology infections due to population aging and increasing co-morbidity, the potential clinical utility of fenticonazole in this area warrants further investigation in large, randomized clinical trials.

## Acknowledgements

Medical writing assistance was provided by Neil Reynolds and Mary Hines of Wolters Kluwer Health Medical Communications with funding from Recordati. The authors have declared that they have no conflicts of interest that are directly relevant to the content of this review.

## References

1. Garber G. An overview of fungal infections. *Drugs* 2001; 61 Suppl. 1: 1-12
2. Fromtling RA. Overview of medically important antifungal azole derivatives. *Clin Microbiol Rev* 1988 Apr; 1 (2): 187-217
3. Veronese M, Salvaterra M, Barzaghi D. Fenticonazole, a new imidazole derivative with antibacterial and antifungal activity: *in vitro* study. *Arzneimittelforschung* 1981; 31 (12): 2133-7
4. Naud P, Matos J, Hammes L, et al. Efficacy and tolerability of fenticonazol for bacterial vaginosis treatment: double-blind study, randomized, prospective, compared to placebo [in Portuguese]. *Rev Bras Med* 2003; 60 (1-2): 67-70
5. Costa A, Veronese M, Ruggeri P, et al. Ultrastructural findings of *Candida albicans* blastoconidia submitted to the action of fenticonazole. *Arzneimittelforschung* 1989 Feb; 39 (2): 230-3
6. Costa AL, Valenti A, Veronese M. Study of the morphofunctional alterations produced by fenticonazole on strains of *Candida albicans*, using the scanning electron microscope (S.E.M.). *Mykosen* 1984 Jan; 27 (1): 29-35
7. Angiolella L, De Bernardis F, Bromuro C, et al. The effect of antimycotics on secretory acid proteinase of *Candida albicans*. *J Chemother* 1990 Feb; 2 (1): 55-61
8. Ghannoum M, Abu Elteen K. Correlative relationship between proteinase production, adherence and pathogenicity of various strains of *Candida albicans*. *J Med Vet Mycol* 1986 Oct; 24 (5): 407-13
9. Cohen J. Review of the latest treatments of vulvovaginal mycoses: role of fenticonazole nitrate (Lomexin) in their treatment [in French]. *Contracept Fertil Sex* 1997 May; 25 (5): 396-403
10. Jones BM, Geary I, Lee ME, et al. Comparison of the *in vitro* activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. *Antimicrob Agents Chemother* 1989 Jun; 33 (6): 970-2
11. Albanese G, Di Cintio R, Giorgetti P, et al. Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder. *Mycoses* 1992 May-Jun; 35 (5-6): 157-9
12. Altmeyer P, Luther H, Klaschka F, et al. A double-blind clinical trial of fenticonazole cream versus naftifine cream applied once daily in patients with cutaneous mycosis. *Curr Ther Res Clin Exp* 1990; 47 (1): 32-42
13. Altmeyer P, Nolting S, Kuhlwein A, et al. Effect of fenticonazole spray in cutaneous mycosis: a double-blind clinical trial versus cyclopyroxolamine spray. *J Int Med Res* 1990 Jan-Feb; 18 (1): 61-7
14. Aste N, Pau M, Cordaro CI, et al. Double-blind study with fenticonazole or bifonazole lotions in pityriasis versicolor. *Int J Clin Pharmacol Res* 1988; 8 (4): 271-3
15. Athow-Frost TA, Freeman K, Mann TA, et al. Clinical evaluation of fenticonazole cream in cutaneous fungal infections: a comparison with miconazole cream. *Curr Med Res Opin* 1986; 10 (2): 107-16
16. Clerico R, Ribuffo A. Efficacy and tolerance of fenticonazole versus miconazole cream. *Int J Clin Pharmacol Res* 1987; 7 (1): 77-81
17. Finzi A, Fioroni A, Monici Preti P, et al. A double blind evaluation of fenticonazole cream 2% and clotrimazole cream 1% in dermatomycoses. *Mykosen* 1986 Jan; 29 (1): 41-4
18. Jung EG, Bisco A, Azzollini E, et al. Fenticonazole cream once daily in dermatomycosis, a double-blind controlled trial versus bifonazole. *Dermatologica* 1988; 177 (2): 104-8
19. Kokoschka EM, Niebauer G, Mounari M, et al. Treatment of dermatomycoses with topical fenticonazole and econazole. *Mykosen* 1986 Jan; 29 (1): 45-50
20. Leiste D, Braun W, Fegeler W, et al. A double-blind clinical trial of fenticonazole (2%) spray versus naftifine (1%) spray in patients with cutaneous mycoses. *Curr Med Res Opin* 1989; 11 (9): 567-75
21. Odeh F, Fabry H, Kuhlwein A, et al. A double-blind clinical trial with a single daily application of fenticonazole lotion versus

- econazole lotion in patients with cutaneous mycosis. *Curr Ther Res Clin Exp* 1990; 47: 22-31
22. Rabbiosi G, Di Silverio A, Mosca M, et al. Treatment of Pityriasis versicolor with foam formulation of two different imidazole derivatives, fenticonazole and econazole. *Derm Clin* 1989; 3: 169-74
  23. Stetter H. Fenticonazole (2% cream) in the treatment of skin diseases due to dermatophytes. *Acta Therapeutica* 1984; 10: 241-8
  24. Vannini P, Difonzo EM, Cordaro CI, et al. New therapeutic approach in skin mycoses: a comparative trial once versus twice daily application of fenticonazole in comparison to miconazole. *Mycoses* 1988 May; 31 (5): 280-4
  25. Aste N, Pau M, Zucca M, et al. Clinical experience with fenticonazole 2% formulation in the treatment of dermatomycoses and pityriasis versicolor. *Int J Clin Pharmacol Res* 1987; 7 (6): 503-6
  26. Di Silverio A, Mosca M, Brandozzi G, et al. Efficacy of fenticonazole in patients with pityriasis versicolor [in Italian]. *G Ital Dermatol Venereol* 1989 Sep; 124 (9): XLVII-L
  27. Fioroni A, Altomare GF, Finzi AF. Esperienza con fenticonazolo crema in unica applicazione giornaliera nelle micosi superficiali. *Ann It Derm Clin Sper* 1987; 41: 311-6
  28. Persi A, Rebora A. Fenticonazole: a clinical trial. *Mykosen* 1985 Apr; 28 (4): 206-9
  29. Pizzino D, Negosanti M, Morganti L, et al. Therapeutic efficacy of fenticonazole and in vitro assessment of its antifungal activity in comparison with other imidazole derivatives [in Italian]. *G Ital Dermatol Venereol* 1988 Sep; 123 (9): XLV-XLVIII
  30. Sartani A, Cordaro CI, Panconesi E. A multicenter trial with a new imidazole derivative, fenticonazole, in superficial fungal skin infections. *Curr Ther Res Clin Exp* 1988; 43 (6): 1194-203
  31. Clerico R. Therapeutical activity of a new imidazole, the fenticonazole, in superficial mycoses [in Italian]. *Dermatol Clin* 1986; 6: 87-90
  32. Fioroni A, Terragni L, Vannini P, et al. Fenticonazole plasma levels during treatment with fenticonazole 2% cream and spray in patients with dermatomycoses. *Curr Ther Res Clin Exp* 1990; 47 (6): 997-1003
  33. Fusetti M, Trimarchi I, Eibenstein A. New therapeutic acquisition in the treatment of otomycosis: an experimental study [in Italian]. *Otorinolaringologia* 1990; 40 (5): 393-8
  34. Lepine J, Sacchetta A, Vargiu G, et al. Safety and efficacy on skin mycoses of a new imidazole derivate: fenticonazole. A report on 28 patients. *Med Praxis* 1984; 4: 1-7
  35. Veronese M, Bertoncini A, Preti PM. Evaluation of the skin retention time of imidazole derivatives. *Mykosen* 1987 Aug; 30 (8): 386-90
  36. Lopez-De-Blanc SA, Salati-De-Mugnolo N, Femopase FL, et al. Antifungal topical therapy in oral chronic candidosis: a comparative study. *Med Oral* 2002 Jul-Oct; 7 (4): 260-70
  37. Brewster E, Preti PM, Ruffmann R, et al. Effect of fenticonazole in vaginal candidiasis: a double-blind clinical trial versus clotrimazole. *J Int Med Res* 1986; 14 (6): 306-10
  38. Gorlero F, Bosco P, Barbieri M, et al. Fenticonazole ovules in the treatment of vaginal *Trichomonas* infections: a double-blind randomized pilot clinical trial. *Curr Ther Res Clin Exp* 1992; 51: 367-76
  39. Gorlero F, Macchiavello S, Pellegatta L, et al. Evaluation of the efficacy and tolerability of two different dosages of fenticonazole vaginal ovules (600mg and 1000 mg) in patients with vaginal trichomoniasis: a controlled, double-blind, randomized clinical trial versus placebo. *Curr Ther Res Clin Exp* 1994; 55 (5): 510-8
  40. Studd JW, Dooley MM, Welch CC, et al. Comparative clinical trial of fenticonazole ovule (600 mg) versus clotrimazole vaginal tablet (500 mg) in the treatment of symptomatic vaginal candidiasis. *Curr Med Res Opin* 1989; 11 (8): 477-84
  41. Wiest W, Azzollini E, Ruffmann R. Comparison of single administration with an ovule of 600mg fenticonazole versus a 500mg clotrimazole vaginal pessary in the treatment of vaginal candidiasis. *J Int Med Res* 1989 Jul-Aug; 17 (4): 369-72
  42. Belaisch J. Evaluation of the time response of a single dose administration of fenticonazole nitrate [in French]. *Contracept Fertil Sex* 1996 May; 24 (5): 417-22
  43. Bukovsky I, Schneider D, Arieli S, et al. Fenticonazole in the treatment of vaginal trichomoniasis and vaginal mixed infections. *Adv Ther* 1991; 8: 166-71
  44. Fernandez-Alba J, Valle-Gay A, Dibildox M, et al. Fenticonazole nitrate for treatment of vulvovaginitis: efficacy, safety, and tolerability of 1-gram ovules, administered as ultra-short 2-day regimen. *J Chemother* 2004 Apr; 16 (2): 179-86
  45. Lawrence AG, Houang ET, Hiscock E, et al. Single dose therapy of vaginal candidiasis: a comparative trial of fenticonazole vaginal ovules versus clotrimazole vaginal tablets. *Curr Med Res Opin* 1990; 12 (2): 114-20
  46. Munoz Reyes JR, Villanueva Reynoso C, Ramos CJ, et al. Efficacy and tolerance of 200mg of fenticonazole versus 400mg of miconazole in the intravaginal treatment of mycotic vulvovaginitis [in Spanish]. *Ginecol Obstet Mex* 2002 Feb; 70: 59-65
  47. Sartani A, Cordaro C, Adinolfi G, et al. Short-term treatment of vaginal candidiasis: results of a multi-center study [in Italian]. *Riv Ost Gin Perin* 1988; 3 (2): 184-9
  48. Schneider D, Caspi E, Arieli S, et al. Fenticonazole in the treatment of vaginal candidiasis. *Adv Ther* 1990; 7: 355-61
  49. Wiest W, Ruffmann R. Short-term treatment of vaginal candidiasis with fenticonazole ovules: a three-dose schedule comparative trial. *J Int Med Res* 1987 Sep-Oct; 15 (5): 319-25
  50. De Cecco L, Gorlero F, Marre Brunenghi MC, et al. Studio multicentrico sull'efficacia e tollerabilita del fenticonazolo nel trattamento delle vulvovaginiti da candida. *Int J Drug Ther* 1988; 5 (4): 296-301
  51. Scalabrino S, Colombo M, Pellegrino A, et al. Efficacy and tolerability of intravaginal fenticonazole single therapeutic shot in low-recurrent vaginal trichomoniasis and candidiasis [in Italian]. *Giorn Ital Mal Inf* 1996; 2: 37-40
  52. Scienza G, Bulgheroni C, Confalonieri C. Vaginiti recidivanti: efficacia e tollerabilita della terapia locale con fenticonazolo. *G Ital Ost Gin* 1987; 9 (9): 758-60

Correspondence: Prof. Stefano Veraldi, Institute of Dermatological Sciences, University of Milan, Via Pace 9, Milan, 20122, Italy.

E-mail: stefano.veraldi@unimi.it